Analysts Forecasting Profitability Indicators: Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) persists its position slightly strong in context of buying side, while shares price plummeted -1.06% during latest trading session. The VRX held a rough session during the week but was ready to get some critical analysis. The stock was assessed by a pool of analysts at WSJ and came out with some serious outcomes not to be avoided before making investment. The VRX ratings chart showed that 14 gave HOLD ratings for the current month as 1 analyst opting for Overweight option for same period, whereas, 1 analyst out of pool gave UNDERWEIGHT rating. For stocks’ current month, 3 analysts opted for BUY ratings as compared to 3 opting for SELL in the same period. The stock price target chart showed average price target of 19.31 as compared to current price of 12.11.

Taking look on per share earnings estimates, its next year first quarter current estimate trend for EPS was for $0.97 and on annual basis FY 2016 estimate trends at current was for $3.92 as compared to one month ago of $5.42, and for next year per share earnings estimates have $4.57.

Narrow down focus to other ratios, the Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has current ratio of 1.40 that indicates if ratio lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Generally, it indicates good short-term financial strength. To make strengthen these views, the active industry firm has Quick Ratio of 1.10, which indicates firm has sufficient short-term assets to cover its immediate liabilities. In addition, the firm has debt to equity ratio of 9.47, sometimes it remain same with long term debt to equity ratio.

Analysts Pools

The VRX held a rough session during the week but was ready to get some critical analysis. The stock was assessed by a pool of analysts at WSJ and came out with some serious outcomes not to be avoided before making investment. The VRX ratings chart showed that 14 gave HOLD ratings for the current month as 1 analyst opting for Overweight option for same period, whereas, 1 analyst out of pool gave UNDERWEIGHT rating. For stocks’ current month, 3 analysts opted for BUY ratings as compared to 3 opting for SELL in the same period. The stock price target chart showed average price target of 19.31 as compared to current price of 12.11.

Taking look on per share earnings estimates, its next year first quarter current estimate trend for EPS was for $0.97 and on annual basis FY 2016 estimate trends at current was for $3.92 as compared to one month ago of $5.42, and for next year per share earnings estimates have $4.57.

Profitability Analysis

To stick with focus on profitability valuation, Valeant Pharmaceuticals International, Inc. (NYSE:VRX) also listed in significant eye catching mover, VRX attains returns on investment ratio of -1.60%, which suggests it’s viable on security that has lesser ROI.

To strengthen this concept we can use profit margin, which is standing at negative -24.90%, and it is providing insight views about a variety of aspects of a firm’s financial performance. The operating profit margin and gross profit margin can be giving more focus view that is -5.90% and 73.00% respectively. Turns back to returns ratios, the co’s returns on assets calculated as -1.60%; that gives an idea as to how efficient management is at using its assets to generate earnings. Finally yet importantly, returns on equity stand at -52.70%.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) stands at -714.90%, and looking further price to next year’s EPS is 17.14%. While take a short look on price to sales ratio, that was 0.44.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *